A phase III, randomized, double-blind, placebo-controlled trial on 808 patients with HER2-positive locally recurrent, unresectable, or metastatic BC, found that the addition of pertuzumab to the trastuzumab and docetaxel CT induced more frequently dysgeusia when compared to placebo. The gene discussed is ERBB2; the disease is breast cancer.